



## Dr. Marius König

resident physician

Allgemeine Innere Medizin | Hausarztmedizin und Notfallmedizin,  
Gastroenterology/Hepatology · Dept. I

### Contact

Dr. Marius König  
Rorschacherstrasse 95  
9007 St. Gallen  
Switzerland

T +41 71 494 9963  
Marius.Koenig@kssg.ch

### Units

Allgemeine Innere Medizin | Hausarztmedizin und Notfallmedizin, Gastroenterology/Hepatology

### Profile Function

resident physician

## Publications (3)

Woelfel S, Dütschler J, König M, Dulovic A, Graf N, Junker D, Oikonomou V, Krieger-Grübel C, Truniger S, Franke A, Eckhold A, Forsch K, Koller S, Wyss J, Krupka N, Oberholzer M, Frei N, Geissler N, Schaub P, STAR SIGN Study Investigators, Albrich W, Friedrich M, Schneiderhan-Marra N, Misselwitz B, Korte W, Bürgi J, Brand S. STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease. *Aliment Pharmacol Ther* 2023; 58:678-691.

Woelfel S, Dütschler J, König M, Graf N, Oikonomou V, Krieger-Grübel C, Truniger S, Franke A, Eckhold A, Forsch K, Wyss J, Krupka N, Albrich W, Frei N, Geissler N, Schaub P, STAR SIGN Study Investigators, Friedrich M, Misselwitz B, Korte W, Bürgi J, Brand S. Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2. *Aliment Pharmacol Ther* 2022; 57:103-116.

Maeder M, König T, Bogdanovic S, Schneider I, Eugster W, Ammann P, König M, Beer J, Rickli H. Quality of vitamin K antagonist oral anticoagulation in 322 patients with atrial fibrillation - real-life data from a survey in Eastern Switzerland. *Swiss Med Wkly* 2017; 147:w14503.

## Projects (5)

### **Frequency and Clinical Significance of PR3- and MPO Antineutrophil Cytoplasmic Antibodies (ANCA) in Ulcerative Colitis and Crohn's Disease (IBD-ANCA Study)**

*Clinical Studies - Jul 1, 2023 - Jul 1, 2025*

*Ongoing*

### **VedolizumAb in IBD - Real-world non-Interventional, Prospective, Observational Study to describe real-world treatment patterns in patients on vedolizumab treatment**

*Clinical Studies - Jul 14, 2022 - Dec 31, 2023*

*Automatically Closed*

### **I6T-MC-AMAX**

*Clinical Studies - Jun 7, 2022 - Dec 31, 2024*

*Ongoing*

### **CED-4/CEL**

*Clinical Studies - Jun 1, 2022 - Dec 31, 2024*

*Ongoing*

### **Analysis of the effect of biological therapy on SARS-CoV-2-specific antibody levels following booster vaccination in patients with inflammatory bowel disease**

*Clinical Studies - Jan 20, 2022 - Mar 30, 2023*

*Automatically Closed*